Efeito da suplementação de glutamina em pacientes oncológicos

Authors

  • Daiane Cristine Nogueira de Lima Tancredo
  • Veridiana Varella
  • Mércia Tancredo

DOI:

https://doi.org/10.55905/oelv22n1-144

Keywords:

câncer, pacientes oncológicos, suplementação, glutamina

Abstract

O câncer, também conhecido como neoplasia maligna, é caracterizado pela perda de controle na proliferação celular. Tornou-se um problema de saúde pública global, afetando cerca de nove milhões de pessoas e causando aproximadamente cinco milhões de mortes a cada ano. É considerado a segunda principal causa de morte por doenças em países desenvolvidos, perdendo apenas para as doenças cardiovasculares. A neoplasia maligna se caracteriza pelo crescimento celular desorganizado e alta capacidade de replicação, promovendo o desvio no metabolismo do hospedeiro, resultando em um intenso estado catabólico e alterações no metabolismo de proteínas, carboidratos e lipídios. As células tumorais podem utilizar vários substratos como fonte de energia, como glicose, lipídios, corpos cetônicos e aminoácidos. A glutamina, um aminoácido sintetizado no sistema esquelético, é secretado pelo sistema sanguíneo e chega aos tecidos. Ela serve como combustível para linfócitos e enterócitos, ajudando no bom funcionamento de neutrófilos, macrófagos e na proliferação linfocitária. As principais células consumidoras de glutamina incluem as células renais, hepáticas e do sistema imunológico. A suplementação de glutamina melhora a imunidade mediada por células e a integridade da mucosa intestinal, preservando a massa magra do corpo. Este estudo realizou uma revisão sistemática sobre a importância da suplementação de glutamina no tratamento de pacientes oncológicos. As bases de dados utilizadas foram PubMed, Scielo, Lilacs e Google Acadêmico. A busca foi realizada entre 2000 e 2017, com atualização bibliográfica entre 2017 e 2023 após a conclusão deste trabalho, mantendo os critérios de inclusão e referenciando adequadamente os artigos que atenderam aos descritores.

References

ACHAMRAH, N.; DÉCHELOTTE, P.; COËFFIER, M. Glutamine and the regulation of intestinal permeability: from bench to bedside. Curr Opin Clin Nutr Metab Care, v. 20, n. 1, p. 86-91, 2017.

AHMED, M. Recent advances in the management of gastrointestinal stromal tumor. World J Clin Cases, v. 8, n. 15, p. 3142-3155, 2020.

ANDERSON, P. M.; LALLA, R. V. Glutamine for Amelioration of Radiation and Chemotherapy Associated Mucositis during Cancer Therapy. Nutrients, v. 12, n. 6, p. 1675, 2020.

ARENDS, J. Malnutrition in cancer patients: Causes, consequences and treatment op-tions. Eur J Surg Oncol, 2023.

BALMAIN, A.; GRAY, J.; PONDER, B. The genetics and genomics of cancer. Nature genetics, v. 33, n. 3, p. 238-244, 2003.

BALZER, M. S.; ROHACS, T.; SUSZTAK, K. How Many Cell Types Are in the Kid-ney and What Do They Do?. Annu Rev Physiol, v. 84, p. 507-531, 2022.

BILLER, L. H.; SCHRAG, D. Diagnosis and Treatment of Metastatic Colorectal Can-cer: A Review. JAMA, v. 325, n. 7, p. 669-685, 2021.

BRITO, C. M. et al. Avaliação nutricional de pacientes onco-hematológicos em quimio-terapia suplementados com glutamina / Nutritional assessment of glutamine-supplemented onco-hematological patients submitted to chemotherapy. Rev. bras. ci-ênc. saúde, v. 20, n. 4, p. 319-326, 2016.

BURRELL, R. A. et al. The causes and consequences of genetic heterogeneity in cancer evolution. Nature, v. 501, n. 7467, p. 338-345, 2013.

CALDER, P. C. Immunonutrition. BMJ, v. 327, n. 7407, p. 117-118, 2003.

CANDEIAS, S. M.; GAIPL, U. S. The Immune System in Cancer Prevention, Devel-opment and Therapy. Anticancer Agents Med Chem, v. 16, n. 1, p. 101-107, 2016.

COBO DOLS, M. et al. Secondary signet-ring cell tumour of the prostate derived from a primary gastric malignancy. Clin Transl Oncol, v. 7, n. 9, p. 409-412, 2005.

CRUZAT, V. et al. Glutamine: Metabolism and Immune Function, Supplementation and Clinical Translation. Nutrients, v. 10, n. 11, p. 1564, 2018.

CRUZAT, V. et al. Glutamine: Metabolism and Immune Function, Supplementation and Clinical Translation. Nutrients, v. 10, n. 11, p. 1564, 2018.

DE CASTRO SANT' ANNA, C. et al. Molecular biology as a tool for the treatment of cancer. Clin Exp Med, v. 18, n. 4, p. 457-464, 2018.

DEMAN, J.; VAN LAREBEKE, N. Carcinogenesis: mutations and mutagens. Tumour Biol, v. 22, n. 3, p. 191-202, 2001.

ELMORE, S. Apoptosis: a review of programmed cell death. Toxicol Pathol, v. 35, n. 4, p. 495-516, 2007.

ERSON, A. E.; PETTY, E. M. Molecular and genetic events in neoplastic transfor-mation. In: SCHOTTENFELD, D.; FREUMENI, J. P. Cancer Epidemiology and Pre-vention, p. 47-64, 2006.

GAURAV, K. et al. Glutamine: A novel approach to chemotherapy-induced toxicity. Indian Journal of Medical and Paediatric Oncology, v. 33, n. 1, p. 13-20, 2012.

GYAMFI, J.; KIM, J.; CHOI, J. Cancer as a Metabolic Disorder. Int J Mol Sci, v. 23, n. 3, p. 1155, 2022.

HAMAKER, M. E. et al. Nutritional status and interventions for patients with cancer - A systematic review. J Geriatr Oncol, v. 12, n. 1, p. 6-21, 2021.

HERNÁNDEZ BORRERO, L. J.; EL-DEIRY, W. S. Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting. Biochim Biophys Acta Rev Cancer, v. 1876, n. 1, p. 188556, 2021.

ISPOGLOU, T. et al. The efficacy of essential amino acid supplementation for aug-menting dietary protein intake in older adults: implications for skeletal muscle mass, strength and function. Proc Nutr Soc, v. 80, n. 2, p. 230-242, 2021.

JAYME, B. et al. Global cancer trends: the changing cancer burden. In: Seminars in oncology nursing, v. 30, n. 3, p. 150-156, 2014.

KARINCH, A. M. et al. Glutamine metabolism in sepsis and infection. J Nutr, v. 131, n. 9 Suppl, p. 2535S-1S, 2001.

KEENAN, M. M.; CHI, J. T. Alternative fuels for cancer cells. Cancer J, v. 21, n. 2, p. 49-55, 2015.

KIM, J. S. et al. Plasma glutathione reductase activity and prognosis of septic shock. J Surg Res, v. 200, n. 1, p. 298-307, 2016.

KUMAR, A. R. et al. Harnessing the immune system against cancer: current immuno-therapy approaches and therapeutic targets. Mol Biol Rep, v. 48, n. 12, p. 8075-8095, 2021.

KURMI, K.; HAIGIS, M. C. Nitrogen Metabolism in Cancer and Immunity. Trends Cell Biol, v. 30, n. 5, p. 408-424, 2020.

LAW, M. L. Cancer cachexia: Pathophysiology and association with cancer-related pain. Front Pain Res (Lausanne), v. 3, p. 971295, 2022.

ŁUKASIEWICZ, S. et al. Breast Cancer - Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies - An Updated Review. Cancers (Basel), v. 13, n. 17, p. 4287, 2021.

MA, G. et al. Reprogramming of glutamine metabolism and its impact on immune re-sponse in the tumor microenvironment. Cell Commun Signal, v. 20, n. 1, p. 114, 2022.

MARTIN, L. et al. Diagnostic criteria for cancer cachexia: reduced food intake and in-flammation predict weight loss and survival in an international, multi-cohort analysis. J Cachexia Sarcopenia Muscle, v. 12, n. 5, p. 1189-1202, 2021.

MARTINS, P. Glutamine in critically ill patients: is it a fundamental nutritional supple-ment?. Rev Bras Ter Intensiva, v. 28, n. 2, p. 100-103, 2016.

MEYNIAL-DENIS, D. Glutamine metabolism in advanced age. Nutr Rev, v. 74, n. 4, p. 225-236, 2016.

MUSCARITOLI, M. et al. ESPEN practical guideline: Clinical Nutrition in cancer. Clinical Nutrition, Edinburgh, v. 40, n. 5, p. 2898-2913, 2021.

NEWSHOLME, P. et al. Glutamine and glutamate--their central role in cell metabolism and function. Cell Biochem Funct, v. 21, n. 1, p. 1-9, 2003.

NEWSHOLME, P. Why is L-glutamine metabolism important to cells of the immune system in health, postinjury, surgery or infection?. J Nutr, v. 131,n .9, p. 2515S-4S, 2021

NI, J.; ZHANG, L. Cancer Cachexia: Definition, Staging, and Emerging Treatments. Cancer Manag Res, v. 12, p. 5597-5605, 2020.

NIKOLOVA, E. et al. Prospects for Radiopharmaceuticals as Effective and Safe Ther-apeutics in Oncology and Challenges of Tumor Resistance to Radiotherapy. Dose Re-sponse, v. 19, n. 1, p. 1559325821993665, 2021.

NOVIKOV, N. M. et al. Mutational drivers of cancer cell migration and invasion. Br J Cancer, v. 124, n. 1, p. 102-114, 2021.

OGDEN, H. B. et al. Acute L-glutamine supplementation does not improve gastrointes-tinal permeability, injury or microbial translocation in response to exhaustive high inten-sity exertional-heat stress. Eur J Sport Sci, v. 22, n. 12, p. 1865-1876, 2022.

OPAS. Organização Pan-Americana da Saúde. Câncer. [Washington] Organização Mundial da Saúde, 2020. Disponível em: https://www.paho.org/pt/topicos/cancer. Aces-so em: 19 ago. 2022.

PAIVA, C. E. et al. The P53 gene and its role in cancer. In: Advances in cancer re-search, v. 131, p. 1-46, 2016.

PENG, L. et al. Glutamine as an energy substrate in cultured neurons during glucose deprivation. J Neurosci Res, v. 85, n. 15, p. 3480-3486, 2007.

PURCELL, S. A. et al. Key determinants of energy expenditure in cancer and implica-tions for clinical practice. Eur J Clin Nutr, v. 70, n. 11, p. 1230-1238, 2016.

RICCIOTTI, E.; FITZGERALD, G. A. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol, v. 31, n. 5, p. 986-1000, 2011.

RICH, N. E. et al. Cachexia is Prevalent in Patients With Hepatocellular Carcinoma and Associated With Worse Prognosis. Clin Gastroenterol Hepatol, v. 20, n. 5, p. e1157-e1169, 2022.

SANT ANA, G. et al. Topical Treatment of Oral Mucositis in Cancer Patients: A Sys-tematic Review of Randomized Clinical Trials. Asian Pac J Cancer Prev, v. 21, n. 7, p. 1851-1866, 2020.

SANTOS, M. de O. et al. Estimativa de Incidência de Câncer no Brasil, Revista Brasi-leira de Cancerologia, 2023.

SCHCOLNIK-CABRERA, A. et al. Understanding tumor anabolism and patient ca-tabolism in cancer-associated cachexia. Am J Cancer Res, v. 7, n. 5, p. 1107-1135, 2017.

SEVERO, J. S. et al. Efeitos da suplementação de glutamina na doença inflamatória intestinal: Uma revisão sistemática de ensaios clínicos. Clin Nutr ESPEN, v. 42, p. 53-60, 2021.

STUBBLEFIELD, M. D. et al. Clin Oncol (R Coll Radiol), v. 17, n. 4, p. 271-276, 2005.

TESSARI, P.; LANTE, A.; MOSCA, G. Essential amino acids: master regulators of nutrition and environmental footprint?. Sci Rep, v. 6, p. 26074, 2016.

TOMÉ, D.; BENOIT, S.; AZZOUT-MARNICHE, D. Protein metabolism and related body function: mechanistic approaches and health consequences. Proc Nutr Soc, v. 80, n. 2, p. 243-251, 2021.

VAIRETTI, M. et al. Changes in Glutathione Content in Liver Diseases: An Update. Antioxidants (Basel), v. 10, n. 3, p. 364, 2021.

VAN DEN BERG, M. M. et al. Weight change during chemotherapy in breast cancer patients: a meta-analysis. BMC Cancer, v. 17, n. 1, p. 259, 2017.

VAN WEVERWIJK, A.; DE VISSER, K. E. Mechanisms driving the immunoregulato-ry function of cancer cells. Nat Rev Cancer, v. 23, n. 4, p. 193-215, 2023.

VENEGAS, D. F.; DE LA FUENTE, M. K.; LANDSKRON, G. et al. Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Rele-vance for Inflammatory Bowel Diseases. Front Immunol, v. 10, p. 277, 2019.

WALKER, M. C.; VAN DER DONK, W. A. The many roles of glutamate in metabo-lism. J Ind Microbiol Biotechnol, v. 43, n. 2-3, p. 419-430, 2016.

WANG, B. et al. Glutamine and intestinal barrier function. Amino Acids, v. 47, n. 10, p. 2143-2154, 2015.

WANG, Y.; HAO, F.; LIU, Y. Pro-Environmental Behavior in an Aging World: Evi-dence from 31 Countries. Int J Environ Res Public Health, v. 18, n. 4, p. 1748, 2021.

Published

2024-01-25

How to Cite

Tancredo, D. C. N. de L., Varella, V., & Tancredo, M. (2024). Efeito da suplementação de glutamina em pacientes oncológicos. OBSERVATÓRIO DE LA ECONOMÍA LATINOAMERICANA, 22(1), 2770–2789. https://doi.org/10.55905/oelv22n1-144

Issue

Section

Articles

Most read articles by the same author(s)